

Case report

Complete robotic intervention for acute epistaxis in a patient with COVID-19 pneumonia: technical considerations and device selection tips

Hamidreza Saber ¹, Charles Beaman ², Satoshi Tateshima^{1,3}

¹Interventional Neuroradiology, UCLA, Los Angeles, California, USA

²Neurology, UCLA Medical Center, Los Angeles, California, USA

³Radiological Sciences, UCLA, Los Angeles, California, USA

Correspondence to

Dr Satoshi Tateshima, Interventional Neuroradiology, Radiological Sciences, UCLA, Los Angeles, California, USA; stateshima@mednet.ucla.edu

Received 28 December 2021
Accepted 20 February 2022

SUMMARY

The use of robot-assisted technology is expanding in interventional laboratories with an increasing number of reports of effective treatment delivery in neurointerventional procedures. Here we report the feasibility of complete robot-assisted neurointervention including the guide catheter and microcatheter manipulations with subsequent embolization of the arterial source of hemorrhage in a patient hospitalized with severe COVID-19 complicated by acute epistaxis.

CASE PRESENTATION

A man in his late 30s with a history of severe COVID-19 with respiratory failure on mechanical ventilation, renal failure and coagulopathy developed acute refractory bilateral epistaxis. Diagnostic angiography and embolization of the arterial source of the hemorrhage were planned using the CorPath GRX Robotic System (Corindus, a Siemens Healthineers Company, Waltham, Massachusetts, USA).¹ Proximal carotid artery selection is included in the current CorPath indications, and the primary operator had completed the phase I training on the robotic system, which includes performing five diagnostic angiograms with a Corindus specialist. The robotic console is positioned outside the angiography suite. It is equipped with a 26-inch monitor to view live biplane fluoroscopic views and controls consisting of three joysticks and a touchscreen. The robotic system is capable of advancing, retracting, and rotating the catheter and guidewire separately. It also includes a side port capable of deploying an additional device such as a coil.

Robotic cerebral angiography was performed under general anesthesia using a femoral artery approach. In an initial manual phase of the procedure, a 5-Fr Pinnacle groin sheath was inserted into the groin and a 90 cm 5-Fr Envoy catheter (Cerenovus) was advanced to the descending aorta prior to loading the catheter into the robot. The catheter was then connected to a co-pilot hemostatic valve and a micro guidewire (V-18 ControlWire, Boston Scientific, Marlborough, Massachusetts, USA) was inserted for subsequent robotic manipulation. The catheter was continuously flushed with heparinized saline and another side port was connected to an extended connection tubing that allowed for contrast injections manually or using a contrast media injector. The robotic arm was then brought into position and the catheter/guidewire

combination was loaded into the single-use cassette and secured to the groin sheath ([figure 1A,B](#)).

The primary operator navigated the catheter to the proximal external carotid artery over the wire robotically while sitting at the console outside the angiography room. At the bedside, the supporting operator monitored flush lines and connection tubing as well as manual contrast injections from the side port as needed. Once the Envoy guiding catheter was placed in an optimal position, the wire was removed. The Envoy was then manually unloaded from the robotic cassette (while maintaining the position in the external carotid artery) and the robot was loaded with a 135 cm Rapidtransit (Cerenovus) microcatheter and a Synchro-14 microwire (Stryker Neurovascular), so that the microcatheter/microwire combination was loaded into the robotic cassette and secured to the Envoy guide sheath ([figure 2](#)). Using the robotic console, the microcatheter was navigated over the microwire into the distal internal maxillary artery in an ideal position for embolization, and then polyvinyl alcohol particles (Boston Scientific 250–355 μ m) embolization was performed. A coil was delivered through the device port and deployed at the tip of the microcatheter using the robot. The same steps were then repeated for the contralateral side. The patient experienced no complications and was medically stable on the day following the procedure.

OUTCOME AND FOLLOW-UP

The embolization was successful with good control of the epistaxis and no future episode of epistaxis occurred.

DISCUSSION

The Corindus robot was originally designed for coronary and peripheral vascular procedures, in which implants are deployed directly from the guiding catheter.^{2–4} For neurointerventional procedures the use of the Corindus robot is limited to the hybrid approach, where the extracranial placement of a guiding catheter and also the navigation of an intermediate catheter is performed manually and the intracranial manipulation of a microcatheter and implants is conducted robotically. To our knowledge, this is the first report on the feasibility of complete robotic neurointervention where both guiding catheter and microcatheter are manipulated by an endovascular robot. The ability to control devices from the console offers multiple advantages



© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Saber H, Beaman C, Tateshima S. *J NeuroIntervent Surg* Epub ahead of print: [please include Day Month Year]. doi:10.1136/neurintsurg-2021-018582




Figure 1 (A,B) Catheter/guidewire combination loaded into the single-use cassette and secured to the groin sheath (A) and navigated robotically into an optimal position for the guiding catheter (B).

in addition to the reduction of the occupational radiation exposure. Lowering the risk of transmission of communicable conditions such as COVID-19 is a tremendous advantage during a pandemic. The surgeon can also operate in a convenient seated position with easy visualization and interaction with the monitor. Although neurointerventionalists will benefit from significantly reduced radiation exposure, there may be increased procedure time and radiation exposure during the learning process. As experience grows, it is expected that increased precision of robotic catheter and device manipulation will ultimately decrease radiation exposure. Prior to performing complete robotic procedures, it is highly recommended that hybrid robotic procedures or extensive in vitro modeling sessions are conducted to reduce procedural time and patient radiation exposure and to maximize the likelihood of a successful robotic procedure. Although the procedure can be completed with only one operating staff member, at this point it is recommended that there should be an operating assistant at the bedside to monitor the lines, adjust the fluoroscopic table and connections, and perform hand injections. Future integration of robotic system controls with fluoroscopic machine functionalities would reduce this need.

The complete robotic procedure poses unique challenges such as the selection of devices, calculating the working length, and maximizing visual information. The guiding catheter,

microcatheter, and coiling procedure were primarily manipulated using a push/pull and rotation joystick control solely based on the visual information (figure 3). Particular attention has to be given to the working length of the catheters with respect to the movement range of the robotic arm. Prior to switching the robotic control from the guiding catheter to the microcatheter, the robot was maximally pulled backward to obtain the full 20 cm of forward working length. With regard to device selection, we recommend using a long guiding catheter that can accept any excessive microcatheter length that is retained outside of the robotic cassette tube. Future robotic designs may be improved by lengthening the robotic cassette tubing to enhance microcatheter compatibility. Obtaining proximal support by the use of a microwire such as Synchro Support helped reduce excessive slack of the microcatheter in the robotic cassette tube.

Coil embolization was feasible with careful attention to the deflection of the coil loops and the microcatheter tip without the need for haptic feedback. Precise and controllable delivery and advancement of the coiling wire and the microcatheter showed promising potential for precise delivery of coil loops in the desired fashion. In our experience, visual attention to coil morphology and friction force by observing subtle changes in the motion of devices was sufficient to perform successful coil embolization.




Figure 2 Demonstration of loading the microcatheter/microguidewire combination into the robotic cassette secured to the Envoy guide sheath.




Figure 3 Manipulation of the microcatheter and coiling procedure performed using a push/pull and rotation joystick control solely based on the visual information.

Learning points

- Complete robotic intervention is feasible by carefully choosing the devices.
- Complete robotic intervention reduces the risk of the operator being exposed to biohazardous materials.
- Particular attention must be paid to the working length of the robot, the length of the guiding catheter, and the length of a portion of the microcatheter that protrudes from the distal and proximal ends of the guiding catheter.
- It is highly recommended that hybrid robotic procedures or extensive in vitro modeling sessions be conducted prior to performing complete robotic procedures.

Recent studies have reported the feasibility of the robotic system for performing hybrid neurointerventional procedures including carotid artery stenting and cerebral coil embolization.^{5–7} In the future, robotic endovascular systems should be able to function remotely on secured networks and be capable of handling triaxial systems. This will hopefully allow for the possibility of telerobotic acute stroke treatment, thus reducing the geographic access gap to these interventions.^{8,9} Our experience of coil embolization of the distal internal maxillary artery feeder in a patient with epistaxis and a history of COVID-19 further highlights the potential and benefit of neurointerventional procedures using robotic systems.

Twitter Charles Beaman @charlesbeaman

Contributors HS and ST contributed to the conception or design of the work. HS, ST and CB contributed to drafting the work and revising it critically for important

intellectual content.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests ST: Corindus Vascular Robotics: advisory board, shareholder from 2018-2019. Currently no relationship. HS and CB have nothing to disclose.

Patient consent for publication Consent obtained from next of kin.

Provenance and peer review Not commissioned; externally peer reviewed.

ORCID iDs

Hamidreza Saber <http://orcid.org/0000-0001-7590-2023>

Charles Beaman <http://orcid.org/0000-0001-5425-8849>

REFERENCES

- 1 Britz GW, Panesar SS, Falb P, *et al.* Neuroendovascular-specific engineering modifications to the CorPath GRX robotic system. *J Neurosurg* 2019;1–7.
- 2 Weisz G, Metzger DC, Caputo RP, *et al.* Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-Enhanced Coronary Intervention) study. *J Am Coll Cardiol* 2013;61:1596–600.
- 3 Mahmud E, Schmid F, Kalmar P, *et al.* Feasibility and safety of robotic peripheral vascular interventions: results of the RAPID trial. *JACC Cardiovasc Interv* 2016;9:2058–64.
- 4 Smilowitz NR, Weisz G. Robotic-assisted angioplasty: current status and future possibilities. *Curr Cardiol Rep* 2012;14:642–6.
- 5 Mendes Pereira V, Cancelliere NM, Nicholson P, *et al.* First-in-human, robotic-assisted neuroendovascular intervention. *J Neurointerv Surg* 2020;12:338–40.
- 6 Sajja KC, Sweid A, Al Saiegh F, *et al.* Endovascular robotic: feasibility and proof of principle for diagnostic cerebral angiography and carotid artery stenting. *J Neurointerv Surg* 2020;12:345–9.
- 7 Nogueira RG, Sachdeva R, Al-Bayati AR, *et al.* Robotic assisted carotid artery stenting for the treatment of symptomatic carotid disease: technical feasibility and preliminary results. *J Neurointerv Surg* 2020;12:341–4.
- 8 Zelenák K, Krajina A, Meyer L, *et al.* How to improve the management of acute ischemic stroke by modern technologies, artificial intelligence, and new treatment methods. *Life* 2021;11:488.
- 9 Beaman CB, Kaneko N, Meyers PM, *et al.* A review of robotic interventional neuroradiology. *AJNR Am J Neuroradiol* 2021;42:808–14.

ICMJE DISCLOSURE FORM

Date: 12/27/2021

Your Name: Charles Beaman

Manuscript Title: Complete Robotic Intervention for Acute Epistaxis in A Patient with COVID-19 Pneumonia: technical considerations and device selection tips

Manuscript Number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>						Click the tab key to add additional rows.
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" data-bbox="415 342 1435 434"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" data-bbox="415 537 1435 630"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" data-bbox="415 730 1435 823"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>									

ICMJE DISCLOSURE FORM

Date: 12/27/2021

Your Name: Hamidreza Saber

Manuscript Title: Complete Robotic Intervention for Acute Epistaxis in A Patient with COVID-19 Pneumonia: technical considerations and device selection tips

Manuscript Number (if known): Unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>						Click the tab key to add additional rows.
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
11	Stock or stock options	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>							
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>									

ICMJE DISCLOSURE FORM

Date: 12/27/2021

Your Name: Satoshi Tateshima

Manuscript Title: Complete Robotic Intervention for Acute Epistaxis in A Patient with COVID-19 Pneumonia: technical considerations and device selection tips

Manuscript Number (if known): unknown

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td>Click the tab key to add additional rows.</td></tr> </table>						Click the tab key to add additional rows.
	Click the tab key to add additional rows.							
Time frame: past 36 months								
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <table border="1"> <tr> <td>Biomedical Solutions, Inc.</td> <td>Research grant, PI.</td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	Biomedical Solutions, Inc.	Research grant, PI.				
Biomedical Solutions, Inc.	Research grant, PI.							
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>						

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	<input type="checkbox"/> None <table border="1"> <tr><td>Medtronic</td><td></td></tr> <tr><td>Stryker</td><td></td></tr> <tr><td>Cerenovus</td><td></td></tr> <tr><td>Spartan Micro</td><td></td></tr> </table>	Medtronic		Stryker		Cerenovus		Spartan Micro		
Medtronic											
Stryker											
Cerenovus											
Spartan Micro											
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	<input type="checkbox"/> None <table border="1"> <tr><td>Irvine Neurovascular</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	Irvine Neurovascular								
Irvine Neurovascular											
8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None <table border="1"> <tr><td>Medtronic</td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>	Medtronic								
Medtronic											
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input checked="" type="checkbox"/> None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	<input type="checkbox"/> None	
		Spartan Micro	Stock option
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input checked="" type="checkbox"/> None	
13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
<p>Please place an "X" next to the following statement to indicate your agreement:</p> <p><input checked="" type="checkbox"/> I certify that I have answered every question and have not altered the wording of any of the questions on this form.</p>			